- Home
- CERS vs GOSS Comparison
CERS vs GOSS Comparison
Compare CERS & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERS
- GOSS
- Stock Information
- Founded
- CERS 1991
- GOSS 2015
- Country
- CERS United States
- GOSS United States
- Employees
- CERS N/A
- GOSS N/A
- Industry
- CERS EDP Services
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- CERS Technology
- GOSS Health Care
- Exchange
- CERS Nasdaq
- GOSS Nasdaq
- Market Cap
- CERS 286.0M
- GOSS 237.9M
- IPO Year
- CERS 1997
- GOSS 2019
- Fundamental
- Price
- CERS $1.81
- GOSS $0.90
- Analyst Decision
- CERS Buy
- GOSS Strong Buy
- Analyst Count
- CERS 3
- GOSS 5
- Target Price
- CERS $3.17
- GOSS $9.20
- AVG Volume (30 Days)
- CERS 1.4M
- GOSS 1.0M
- Earning Date
- CERS 03-04-2025
- GOSS 03-04-2025
- Dividend Yield
- CERS N/A
- GOSS N/A
- EPS Growth
- CERS N/A
- GOSS N/A
- EPS
- CERS N/A
- GOSS N/A
- Revenue
- CERS $176,229,000.00
- GOSS $105,322,000.00
- Revenue This Year
- CERS $21.42
- GOSS N/A
- Revenue Next Year
- CERS $11.12
- GOSS N/A
- P/E Ratio
- CERS N/A
- GOSS N/A
- Revenue Growth
- CERS 14.71
- GOSS N/A
- 52 Week Low
- CERS $1.38
- GOSS $0.50
- 52 Week High
- CERS $2.59
- GOSS $1.60
- Technical
- Relative Strength Index (RSI)
- CERS 57.20
- GOSS 50.80
- Support Level
- CERS $1.74
- GOSS $0.83
- Resistance Level
- CERS $1.87
- GOSS $1.04
- Average True Range (ATR)
- CERS 0.10
- GOSS 0.10
- MACD
- CERS 0.03
- GOSS -0.01
- Stochastic Oscillator
- CERS 79.49
- GOSS 30.65
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.